$Venetoclax combination therapy with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukaemia$

Venetoclax combination therapy with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukaemia

In recent years, one of the most successful advances in treating acute myeloid leukaemia (AML) has been the combination of the B-cell lymphoma 2 (BCL-2) inhibitor venetoclax with hypomethylating agents (decitabine or azacytidine). This combination treatment has an accelerated approval by the Food an...

Full description

Bibliographic Details
Main Authors:	Nerea Báez-Gutiérrez, Héctor Rodríguez-Ramallo, María Antonia-Pérez Moreno, Eduardo-Rodriguez Arboli, Laila Abdel-kader Martín
Format:	Article
Language:	English
Published:	SAGE Publishing 2021-08-01
Series:	Therapeutic Advances in Hematology
Online Access:	https://doi.org/10.1177/20406207211040335

Similar Items

Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies
by: Jonathan Feld, et al.
Published: (2021-04-01)

Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center
by: Matthew E. Tenold, et al.
Published: (2021-03-01)

Targeting the epigenetic state of refractory and relapsing acute myeloid leukaemia
by: Ojong Besong, Ojong Tabi
Published: (2021)

Venetoclax Combined with Hypomethylating Agents for Treatment-Naïve B/Myeloid Mixed Phenotype Acute Leukemia
by: Di Wu, et al.
Published: (2021-01-01)

Update on the role of venetoclax and rituximab in the treatment of relapsed or refractory CLL
by: James D’Rozario, et al.
Published: (2019-05-01)

The myeloid sarcoma treated by Venetoclax with hypomethylating agent followed by stem cell transplantation: rare case report
by: Aleksina Shatilova, et al.
Published: (2021-05-01)

Venetoclax-Based Regimens for Relapsed/Refractory Acute Myeloid Leukemia in a Real-Life Setting: A Retrospective Single-Center Experience
by: Matteo Piccini, et al.
Published: (2021-04-01)

Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis
by: Vikram J. Premkumar, et al.
Published: (2021-01-01)

Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia
by: Huber H, et al.
Published: (2017-02-01)

The cost-effectiveness of treatment of relapsed/refractory chronic lymphocytic leukemia with a combination of venetoclax and rituximab
by: Alla V Rudakova, et al.
Published: (2019-06-01)

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
by: Davids, Matthew S., et al.
Published: (2017)

Refractory Autoimmune Cytopenias Treated With Venetoclax
by: Max J. Gordon, et al.
Published: (2019-06-01)

Arsenic trioxide synergistically promotes the antileukaemic activity of venetoclax by downregulating Mcl-1 in acute myeloid leukaemia cells
by: Hyunsoo Cho, et al.
Published: (2021-04-01)

Rituximab for the treatment of relapsed/refractory chronic lymphocytic leukaemia
by: J Dretzke, et al.
Published: (2010-10-01)

Efficacy of combination of venetoclax with azacitidine or chemotherapy in refractory/relapse acute leukemias of ambiguous lineage, not otherwise specified
by: Kaiqi Liu, et al.
Published: (2021-09-01)

Granulocytic Sarcoma in an Adult with Relapsed Acute Myeloid Leukaemia
by: Neethu Ann Kurien, et al.
Published: (2016-01-01)

Venetoclax-containing regimens in acute myeloid leukemia
by: Ibrahim Aldoss, et al.
Published: (2021-02-01)

Relapsed/Refractory ETP-ALL Successfully Treated With Venetoclax and Nelarabine as a Bridge to Allogeneic Stem Cell Transplant
by: Ashley McEwan, et al.
Published: (2020-06-01)

Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia
by: Paul J. Hampel, et al.
Published: (2021-03-01)

Hypomethylating Agents (HMAs) as Salvage Therapy in Relapsed or Refractory AML: An Italian Multicentric Retrospective Study
by: Federica Lessi, et al.
Published: (2021-08-01)

Treatment for Relapsed/Refractory Acute Myeloid Leukemia
by: Felicitas Thol, et al.
Published: (2021-06-01)

VENETOCLAX FOR RELAPSED ACUTE MYELOID LEUCEMIA AS A “BRIDGE FOR ALLOGENEIC HEMATOPOEITIC STEM CELL TRANSPLANT”: A CASE REPORT
by: A.P. Udo, et al.
Published: (2020-11-01)

Treatment of relapsed/refractory CLL with Venetoclax-Rituximab during the COVID-19 pandemic: A daily-life experience in southern Italy.
by: Stefano Molica, et al.
Published: (2021-06-01)

Efficacy of Venetoclax Combined with Decitabine-Based Treatment for Heavily Pre-Treated Relapsed or Refractory AML Patients in a Real-World Setting
by: Tong J, et al.
Published: (2021-07-01)

Venetoclax in relapsed/refractory blastic plasmacytoid dendritic cell neoplasm with central nervous system involvement: a case report and review of the literature
by: Nil Albiol, et al.
Published: (2021-06-01)

Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
by: Nestor R. Ramos, et al.
Published: (2015-04-01)

Relapsed Chronic Lymphocytic Leukaemia with Concomitant Extensive Chronic Graft versus Host Disease after Allogeneic Haematopoietic Stem Cell Transplantation Successfully Treated with Oral Venetoclax
by: Ching Soon Teoh, et al.
Published: (2021-01-01)

Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML
by: Sakshi Jasra, et al.
Published: (2021-01-01)

Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose
by: Stefanie Jilg, et al.
Published: (2019-04-01)

Recent advances of targeted therapy in relapsed/refractory acute myeloid leukemia
by: Jiale Ma, et al.
Published: (2021-01-01)

B Cell Deficiency in Patients with Relapsed and Refractory Acute Myeloid Leukemia
by: Meghali Goswami, et al.
Published: (2020-07-01)

Timed Sequential Salvage Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia
by: Bogdan Popescu, et al.
Published: (2019-12-01)

Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions
by: Bachar Samra, et al.
Published: (2020-11-01)

Cost-Effectiveness Analysis of Tisagenlecleucel in the Treatment of Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia in Children and Young Adults in Spain
by: Ribera Santasusana JM, et al.
Published: (2020-05-01)

Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents
by: Jane Merlevede, et al.
Published: (2016-02-01)

Low-dose hypomethylating agent decitabine in combination with aclacinomycin and cytarabine achieves a better outcome than standard FLAG chemotherapy in refractory/relapsed acute myeloid leukemia patients with poor-risk cytogenetics and mutations
by: Li L, et al.
Published: (2018-10-01)

Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points
by: Naseema Gangat, et al.
Published: (2020-11-01)

OBATOCLAX REDUCES CELL VIABILITY OF ACUTE MYELOID LEUKEMIA CELLS INDEPENDENTLY OF THEIR SENSITIVITY TO VENETOCLAX
by: K. Lima, et al.
Published: (2020-11-01)

Venetoclax and alvocidib are both cytotoxic to acute myeloid leukemia cells resistant to cytarabine and clofarabine
by: Rie Nishi, et al.
Published: (2020-10-01)

Venetoclax and Decitabine for T/Myeloid Mixed-Phenotype Acute Leukemia Not Otherwise Specified (MPAL NOS)
by: Heather Klocke, et al.
Published: (2020-01-01)